Hundreds of millions of people around the world suffer from back and joint issues, causing serious pain and impacting their ability to move with freedom and ease. Isn’t it time we changed this?

At Trepso Therapeutics, we’re developing a therapy to relieve pain, regenerate tissue, and restore function and quality of life in those suffering from degenerative disc and articular joint diseases.

Trepso’s dual-mechanism therapy treats both the symptoms and the underlying pathology of disc and joint damage. It’s not an opioid, nor a steroid, nor an unknown cocktail of growth factors: it’s a novel, proprietary, and targeted peptide to rebuild disc tissue and rapidly inhibit inflammation and pain.

Trepso’s proprietary and regenerative sLink N (short Link N) peptide is a novel dual-mechanism approach to rebuild disc tissue and rapidly inhibit inflammation and pain. We are currently focusing our efforts on IVDD and OA, which are typically managed symptomatically because there are no commercially available agents proven to arrest or reverse the progression of these diseases. Link N is a naturally occurring peptide and key regulator in maintaining disc and cartilage integrity and health. It provides endogenous feedback to support tissue remodeling by balancing the degradation and rebuilding processes. sLink N is an eight-amino-acid active, commercially viable and functionally equivalent fragment of Link N, retaining all its full biological activity. sLink N differentiates itself from other IVDD and OA treatment approaches by reversing structural deterioration at the same time as blocking the inflammatory- and pain-producing pathways. Further, sLink N therapy treats pain directly, and not just as a consequence of repairing and rebuilding disc tissue. Trepso’s research shows sLink N inhibits and reverses the expression of inflammatory cytokines and the neurogenic factors implicated in disc and osteoarthritic pain. Our in vivo research to date shows sLink N regenerates proteoglycan and collagen content, restores disc height, prevents OA degeneration, and restores cartilage. Trepso’s sLink N exhibits the ideal characteristics for an IVDD or OA therapeutic, with the potential to change the game for the millions of people who suffer from disc degeneration and osteoarthritis.